- Home
- PLUR vs RLYB Comparison
PLUR vs RLYB Comparison
Compare PLUR & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PLUR | RLYB |
|---|---|---|
| Founded | 2001 | 2018 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.9M | 28.7M |
| IPO Year | 2001 | 2021 |
Fundamental Metrics
Financial Performance| Metric | PLUR | RLYB |
|---|---|---|
| Price | $3.31 | $9.46 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 2 |
| Target Price | ★ $12.00 | N/A |
| AVG Volume (30 Days) | 6.3K | ★ 243.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 10.78 | ★ 27.72 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,336,000.00 | $600,000.00 |
| Revenue This Year | $97.38 | $17.61 |
| Revenue Next Year | $293.97 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 309.82 | N/A |
| 52 Week Low | $2.82 | $0.22 |
| 52 Week High | $7.13 | $11.49 |
Technical Indicators
Market Signals| Indicator | PLUR | RLYB |
|---|---|---|
| Relative Strength Index (RSI) | 51.27 | 71.26 |
| Support Level | $3.13 | $0.48 |
| Resistance Level | $3.91 | $11.49 |
| Average True Range (ATR) | 0.16 | 0.89 |
| MACD | -0.03 | -0.09 |
| Stochastic Oscillator | 44.07 | 68.17 |
Price Performance
Historical ComparisonAbout PLUR Pluri Inc.
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.
About RLYB Rallybio Corporation
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. The programs of the company are for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.